Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris

Phase 2

Completed

• Conditions: Psoriasis Vulgaris
• Interventions: Drug: TC cream; Drug: Vehicle

• Registration Number: NCT03372811
• Lead Sponsor: Psoriasis Research Institute of Guangzhou

Brief Summary

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Controlled, Two-Center, Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of TC cream In Treating Patients with Psoriasis Vulgaris

Detailed Description

Not available

Study Timeline

• Study Start: 2015-06-11
• Study First Submitted: 2017-11-30
• Study First Submitted QC: 2017-12-08
• Study First Posted: 2017-12-14
• Primary Completion: 2018-03-14
• Study Completion: 2018-06-30
• Status Verified: 2019-05
• Last Update Submitted: 2019-05-15
• Last Update Posted: 2019-05-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

• Age of 18-70 years old. Both men and women and members of all races and ethnic groups
• Consistent with diagnostic criteria of stable phase psoriasis vulgaris and have at least two target lesions suitable for evaluation
• Women of childbearing age must be using birth control strategies defined by one of the following: 1) a barrier method (condom) and/or 2) oral contraceptives, during the 8-week study period.
• ISGA score ≥ 2 (at least mild severity)
• BSA (stable stage group): 1%≤ to ≤20%
• Signed a written informed consent document
• No additional exposure to the sun

Exclusion Criteria

• Subjects in pregnancy, preparing for pregnancy or breast feeding

• History of hyperergic or photosensitivity

• History of complicated cardiovascular diseases, cerebrovascular diseases, severe primary diseases of hepatic, kidney and hematopoietic system, or patients with psychiatric disorders

• History of photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosa

• Within 4 weeks prior to randomizations, patients have taken treatment with following approved or investigational psoriasis therapies on the target lesions:

  • Topical treatments
  • PUVA, UVB or Grenz ray therapy.
  • Any systemic treatments other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin D analogues, hydroxycarbamide, azathioprine, methotrexate, cyclosporine, other immunosuppressant).
  • Any types of other investigational therapies for psoriasis

• Within 3 months prior to randomizations, patients have taken systemic treatments with retinoids or biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab).

• Planned initiation of, or changes to, concomitant medications that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study.

• History of allergic reactions attributed to compounds of similar chemical or biologic compositions to Coumarins.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
TC cream (10%)	TC cream	-
Vehicle	Vehicle	-

Primary Outcome Measures

Name	Time	Method
Change in Investigator's Static Global Assessment Scale (ISGA) scores of target lesions	up to 12 weeks	ISGA is a static measurement of the psoriasis status performed by physicians. A 6-point ordinal scale from 0 (minimum) to 5 (maximum) is used for estimation with 0 representing completely clear and 5 for very severe. An ISGA score improvement of ≥2 from baseline is considered an improved outcome.

Secondary Outcome Measures

Name	Time	Method
Change in Psoriasis Area and Severity Index (PASI) scores	up to 12 weeks	PASI is the most extensively used tool to measure severity of psoriasis by combing the severity of lesions (erythema, induration and desquamation) and affected area into one single score. Scale ranges from 0 (no disease) to 72 (maximal disease)
Change in Dermatology Life Quality Index (DLQI) scores	up to 12 weeks	DLQI is calculated by summing the score of all questions in questionnaire to measure the impact of psoriasis on the quality of life of a patient. The score ranges from 0 (minimum) to 30 (maximum) with lower scores associated with a better quality of life.
Change in Psoriasis Disability Index questionnaire (PDI) scores	up to 12 weeks	PDI is used to quantify the impact of psoriasis on quality of patients' daily life. The scale ranges from 0 (minimum) to 90 (maximum) with higher scores indicating impaired quality of life.

Trial Locations

Locations (2)

Department of Dermatology, State University of New York, Downstate Medical Center; 🇺🇸 New York, New York, United States

Dermatology Associates; 🇺🇸 Seattle, Washington, United States